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We assessed the external validity of a prediction rule for nonseminomatous testicular cancer patients. The rule was developed to
predict the probability of retroperitoneal metastases being benign (only necrosis/fibrosis) after chemotherapy treatment. Patients
with a high probability of benign residual masses might be offered surveillance as opposed to patients with a low probability, who
should undergo retroperitoneal lymph node dissection (RPLND). We compared the observed histology with the predicted
probability in 105 patients with good prognosis germ cell cancer who underwent RPLND between 1995 and 1998. We found that
predicted probabilities higher than 5% were in good agreement with the observed frequencies of benign masses. The area under the
receiver operating characteristic curve was 0.76, suggesting that the rule could reasonably discriminate between benign masses and
tumour. However, nearly all predicted probabilities (n¼101) were lower than 70%, which might be considered as the lowest value at
which surveillance offers a reasonable alternative to RPLND. Further, 35% of patients currently under surveillance (84 out of 241) had
predicted probabilities lower than 70%. In conclusion, the clinical relevance of the prediction rule was limited for the patients who
underwent RPLND; use of the rule would change the policy from RPLND to surveillance in only a few. On the other hand, the rule
might support selection of patients for RPLND, who currently are under surveillance.
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Computer tomography (CT) often shows small remnants of
retroperitoneal masses after chemotherapy for metastatic non-
seminomatous testicular cancer (Peckham, 1988). The histology of
the residual masses may be benign (entirely necrotic/fibrotic), or
may contain tumour elements (mature teratoma or viable cancer
cells). Resection of a totally benign mass has no therapeutic value
and should preferably not be performed. Most resection policies
consider only one prognostic factor to predict the histology of
residual masses, that is, mass size after chemotherapy (Jansen et al,
1991; Mead et al, 1992). Masses smaller than or equal to 10mm are
generally not resected, although more aggressive approaches have
been proposed (Gelderman et al, 1986; Fossa ˚ et al, 1992).
Mass size as a single prognostic factor has limited predictive
power to discriminate benign histology from tumour. Some small
masses containing tumour are left unresected and larger benign
masses are unnecessarily removed. A distinction based on several
prognostic factors has the potential to classify masses more
accurately as benign or tumour (Donohue et al, 1987; Fossa ˚ et al,
1992). Therefore, a clinical prediction rule has been developed that
incorporates six well-known prognostic factors, that is, the
Residual Histology in Testicular Cancer (ReHiT) prediction rule
(Steyerberg et al, 1995). It estimates the probability that a residual
mass is completely benign. The predicted probability may support
the treating physician in deciding whether a residual mass should
be resected or not.
Before any wide use of a prediction rule can be encouraged, its
ability to produce accurate predictions for patients from different
but plausibly related populations (‘transportability’) needs to be
assessed (Justice et al, 1999). The ReHiT prediction rule was
developed for good, intermediate, and poor prognosis patients
according to the International Germ Cell Consensus Classification
(IGCCG, 1997) on the basis of data from patients from six European
and US study groups (development population), who were
predominantly treated in the 1980s with cisplatin-based chemother-
apy. Patients with a good prognosis (56% of all nonseminomas)
have an expected 5-year progression-free survival probability of
89% (IGCCG, 1997). In this group, particularly, it is important to
minimise the therapeutic burden; any unnecessary treatment such
as resection should be avoided. We therefore studied the transport-
ability of the prediction rule to good prognosis patients treated in
the 1990s. We were particularly interested in the clinical relevance of
the prediction rule, that is, its ability to support decision-making for
patients after chemotherapy.
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Patients participated in an EORTC/MRC trial of the genitourinary
group (EORTC-30941/MRC-TE20), which compared three cycles of
bleomycin, etoposide, cisplatin (3BEP) with four cycles (3BEP–
1EP) and the administration of BEP over 5 days with 3 days (de
Wit et al, 2001). A total of 812 good prognosis patients were
enrolled between March 1995 and April 1998 (Figure 1). The
present analysis included only nonseminomas (n¼682), which are
defined as good prognosis disease when the site of the primary
tumour is not mediastinal, no nonpulmonary visceral metastases
are present, and the marker levels are good, that is, a-fetoprotein
(AFP) and human chorionic gonadotropin (HCG) below
1000ngml
 1 and lactate dehydrogenase (LDH) below 1.5 upper
limit of the normal value (IGCCG, 1997). Patients with an
extragonadal primary site (n¼21), patients having no retro-
peritoneal metastasis (n¼182), and patients with elevated markers
after chemotherapy (n¼68) were excluded from the analysis. Out
of the remaining 411 patients, 306 patients with a prechemother-
apy retroperitoneal metastasis did not undergo retroperitoneal
lymph node dissection (RPLND), either because the CT was
considered to be normal following chemotherapy (n¼241) or for
other reasons (n¼65, e.g. uncompleted chemotherapy). This
meant that 105 patients were analysed for the relation between the
predicted probabilities and the observed histologies (validation
population); 241 patients were analysed for the predicted
probabilities only. Histological findings at RPLND were classified
as benign or tumour. Lesions classified as benign contained only
necrotic or fibrotic elements, while tumour contained mature
teratoma or viable cancer cells.
The prediction rule was developed in 544 patients and
was described in detail before (Steyerberg et al, 1995). The
following patient characteristics are needed to calculate the
probability of benign histology: the absence/presence of teratoma
elements in the primary tumour, determined as teratoma
differentiated (TD) or malignant teratoma intermediate (MTI);
prechemotherapy levels of the serum markers AFP, HCG and LDH;
maximal transversal mass size measured on CT before and after
chemotherapy.
The exact formula is:
sumscore ¼  0:98 þ 0:86ðteratoma-negativeÞ
þ0:87ðAFPnormalÞþ0:76ðHCGnormalÞ
þ0:97ðln½LDHst Þ   0:28ðsqrt½postsize Þ
þ0:15ðreductionÞ
The variables teratoma-negative, AFPnormal, and HCGnormal
are 1 if true and 0 if false. Ln[LDHst] is the natural logarithm of
LDH/upper limit of the normal value range, sqrt[postsize] is the
square root of postchemotherapy transverse diameter expressed in
millimetres, and reduction is the reduction (per 10%) in mass size
during chemotherapy: ((presize postsize)/presize)*10. The prob-
ability of benign histology is calculated with the formula:
probability¼1/(1+e
 sumscore).
This complex formula has been transformed into a score chart
(Steyerberg et al, 1995) for easy estimation of the predicted
probability. The value of each variable corresponds to a number of
points and the total number of points corresponds directly to the
predicted probability. The formula is also implemented in a
spreadsheet, which is available in the public domain (ReHiT
spreadsheet, http://www.eur.nl/fgg/mgz/software.html).
Missing predictor values (2% of all required values) were
imputed based on the correlation with the other predictor
variables (He and Shen, 1997). The statistical performance of the
prediction rule was studied with respect to calibration and
discrimination. Calibration refers to the agreement between the
predicted probabilities and the observed frequencies. Calibration
was studied graphically (Harrell, 1997) and tested with the
Hosmer–Lemeshow test for external validation (Hosmer and
Lemeshow, 1989). Discriminative ability, that is, whether the
relative ranking of individual predictions is in the correct order,
was determined with the area under the receiver operating
characteristic (ROC) curve (ROC area) (Harrell et al, 1982). The
ROC area represents the likelihood that a patient with a benign
mass has a higher predicted probability of benign histology than a
patient with tumour for a random pair of patients with different
histological masses.
To classify masses as benign or tumour using the prediction
rule, we applied a threshold value of 70% (Steyerberg et al, 1999a).
Masses with predicted probabilities higher than 70% were
considered benign; masses with probabilities lower than 70%
were considered to contain tumour. Using the threshold value, we
could study the clinical relevance of the prediction rule for the
current population. Clinical relevance was expressed as the
proportion of patients, who would receive an alternative treatment,
if the prediction rule was applied (i.e. surveillance instead of
RPLND).
Calculations were performed with SAS version 6.12 and S-plus
version 4.5 software, using the Hmisc and Design library (Harrell,
1997).
RESULTS
Table 1 shows the distributions of patient characteristics in the
development population and in the validation population. Merely
26% (27 out of 105) of the patients in the validation population,
which only contained patients with good prognosis disease, had
totally benign residual masses. The distributions of the preche-
motherapy levels of AFP and HCG and of the histology of the
primary tumour were similar across the populations. The
validation population contained a far greater number of patients
in whom LDH level was normal (72% vs 28%), which follows from
the definition of good prognosis; LDH level should be less than 1.5
times the upper normal value. The postchemotherapy mass size
was larger than 10mm in 92% of all patients. A very large
Good prognosis
n = 812
Pure seminoma
n =130
Extragonadal primary
n = 21
No retroperitoneal
 mass
 n = 182
Elevated markers
 after chemotherapy 
n = 68
Nonseminoma
n = 682
Retroperitoneal
metastases
n = 411
Nonevaluable
n = 65
Normal CT after
 chemotherapy
n = 241
Residual masses resected
evaluable for analysis
n = 105
Figure 1 Selection of 105 patients from the EORTC-30941/MRC-TE20
study for whom the prediction rule could be validated.
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only 6% of the validation population.
Figure 2 shows the calibration of the prediction rule. The ideal
curve represents equality of predicted probabilities and observed
frequencies. More than 80% of all patients had predicted
probabilities for benign histology smaller than 50%, which is in
agreement with the low proportion of patients who actually had
benign masses (26%). The Hosmer–Lemeshow test for external
validation indicated a poor fit (P¼0.001). This was caused by
three out of 22 patients with a benign histology, while predicted
probabilities for benign histology were below 5%. The fit was
satisfactory, when these three patients were excluded. The ROC
area was 0.76 (95% confidence interval: 0.65–0.88), which
indicates reasonable discrimination.
At the threshold value of 70%, only four masses (4%) were
classified as benign and would have received surveillance, had the
rule been applied. Thus, the clinical relevance of the rule was
limited. Three of the four masses were indeed completely benign.
Of the 101 masses, 77 (76%) considered as tumour actually
contained tumour. Some 84 of the 241 masses, which were not
resected (35%) had predicted probabilities of benign histology
under 70% and would be considered as tumour.
DISCUSSION
This study shows a reasonable statistical performance of the ReHiT
prediction rule for residual mass histology of nonseminomatous
testicular cancer in 105 recently treated patients with good
prognosis disease. However, the clinical relevance of the rule was
disappointing for these patients.
The prevalence of benign masses was low, that is, 26% in
contrast to 45% in the development population. This may seem
surprising, since we only considered patients with good prognosis
disease. However, the studied patients were a selection of all good
prognosis patients. Predominantly, patients with residual masses
larger than 10mm were candidates for resection and included in
the validation population (92% vs 70% of the development
population). It is well-known that small masses are more often
benign. If more good prognosis patients with very small masses
Table 1 Distribution of the characteristics of nonseminomatous testicular cancer patients undergoing
resection; n (%)
Patient characteristics
Development population
n=544
Validation population
n=105
Predictors
Primary tumour histology
Mature teratoma negative 252 (46) 56 (53)
Prechemotherapy AFP level
Normal 186 (34) 33 (31)
Prechemotherapy HCG level
Normal 205 (38) 50 (48)
Prechemotherapy LDH level
Normal 151 (28) 76 (72)
Postchemotherapy mass size (mm)
0–10 165 (30) 8 (8)
11–20 124 (23) 40 (38)
21–50 139 (26) 40 (38)
>50 116 (21) 17 (16)
Change in mass size during chemotherapy
X70% reduction 161 (30) 6 (6)
0–69% reduction 341 (63) 67 (64)
1–24% progression 10 (2) 13 (12)
X25% progression 32 (6) 19 (18)
Outcome
Worst residual histology
Benign 245 (45) 27 (26)
Tumour 299 (56) 78 (75)
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Figure 2 Calibration curve of the prediction rule in patients of the
EORTC-30941/MRC-TE20 study. Vertical lines at the bottom indicate the
distribution of the predicted probabilities; lines upwards represent patients
with a benign mass, lines downwards patients with tumour. Triangles
indicate the frequency of benign masses grouped per quintile of predicted
probabilities. The solid line shows the relation between predicted
probabilities and observed frequencies. Ideally, this line equals the dotted
line.
Validity of predictions for residual mass histology
Y Vergouwe et al
845
British Journal of Cancer (2003) 88(6), 843–847 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yhad undergone resection, the proportion of benign residual masses
would have been higher.
In total, 30% of all patients (32 out of 105) had larger masses
after chemotherapy than before, compared with 8% of the patients
in the development population. Ignoring the 13 masses that were
enlarged by less than 25% (which may simply reflect measurement
error) reduces the proportion of enlarged masses to 18% (19 out of
105).
Low predicted probabilities showed disagreement with the
observed frequencies, while higher predicted probabilities were
well calibrated (Figure 2). Since a physician will choose
surveillance over resection only if the predicted probability for
benign histology is relatively high, the rule can still be valuable in
that decision-making process. A larger sample size would,
however, be required to provide solid evidence of adequate
calibration.
Discriminative ability depends, apart from the studied
model, also on the patients to whom the model is applied. If the
predictor values of the patients show little variability (homo-
geneous population), it is difficult to distinguish between patients
with different outcomes. Therefore, an ROC area of 0.76 is
considered reasonable for our more homogeneous validation
population containing only patients with good prognosis disease.
A model with the same six predictor variables developed with the
validation data resulted in a slightly larger ROC area (0.78). This
confirms the finding that the original model was statistically valid
for the good prognosis patients, even though the small sample size
and the large confidence interval of the ROC area leave some room
for doubt.
If a threshold value of 70% was used for the present patients,
only four patients (4%) would be classified as benign. Thus,
surveillance would be chosen over resection for 4% of the resected
patients. Therefore, application of the model would have little
clinical relevance for the present candidates of resection.
We also studied the clinical relevance of simpler models. If all
patients with masses p10mm were to be offered surveillance,
eight patients would have been denied resection of whom five had
tumour. Considering mass size (p10mm) together with the
primary tumour histology (mature teratoma elements absent)
would have resulted in only two patients being offered surveillance
of whom one still had tumour. This suggests that simpler models
are not to constitute good alternatives in good prognosis patients.
Better discriminating selection models are required, to reduce the
morbidity of treatment in these patients.
One-third of the patients who did not undergo resection because
of small residual masses had predicted probabilities of benign
histology under 70%, which indicates a substantial risk for residual
tumour. A number of these patients should have been can-
didates for resection, particularly since the risks of short-term
morbidities associated with resection are probably low given the
size of the residual masses (Gels et al, 1997). The patients mainly
had mature teratoma-positive primaries, elevated prechemother-
apy levels of AFP or HCG or a low LDH level. Thus, the prediction
rule could be particularly relevant in identifying small masses
containing tumour. Future studies are required among
patients currently offered surveillance to evaluate the role of the
prediction rule.
To classify masses as benign or tumour using the prediction
rule, we applied a threshold value of 70%. The assessment of a
sensible threshold value is often difficult. We previously found that
the policy to resect all masses larger than 10mm had an implicit
threshold value of 62% (Steyerberg et al, 1999b). A more stringent
policy such as resection in all patients, except in those with masses
smaller or equal to 20mm, having a teratoma-negative primary
tumour, and normal prechemotherapy levels of AFP and HCG
(Fossa ˚ et al, 1992) implied a threshold value of 85%. A threshold
value of 70 or 80% therefore seems reasonable.
Like any scientific hypothesis, the transportability of a
prediction rule is established by being tested and being found
valid across increasingly diverse settings (Justice et al, 1999). The
more numerous and diverse the settings in which the rule is
tested and found valid, the more likely it is that it will be
transportable to an untested setting. Previously, we demonstrated
the statistical performance of the prediction rule in a population
of the late 1980s (Table 2), which was rather similar to
the development population (Steyerberg et al, 1998). The
rule systematically predicted too high probabilities, for patients
treated between 1985 and 1999 at Indiana University Medical
Center (Vergouwe et al, 2001). For these patients, a simple
adjustment of the prediction rule would result in better calibrated
probabilities.
The rule was mainly clinically relevant for the patients from the
development and first validation populations. Around 30% of the
masses in these patients might have been considered benign and
consequently would have been treated by surveillance. The clinical
relevance was poor for the good prognosis patients from the
present study (4% would have been treated by surveillance).
In conclusion, the prediction rule for residual mass histology is
statistically valid in diverse settings. Given the small number of
patients in the current study, the validity in good prognosis
patients is still not fully certain. Although the clinical relevance
was low for the resected patients, the rule may be valuable to
identify candidates for resection among these with masses smaller
than 10mm containing tumour.
Table 2 Studies performed to validate the ReHiT prediction rule for nonseminomatous testicular cancer
Hospitals/groups Years n Prognosis
Percentage
benign
masses Calibration Discrimination
Clinical
relevance
Development Six study groups from 1979–92 544 Good/int/poor 45 OK AUC=0.83 142/544 (26%) cons nec
Europe and US 116/142 (82%) correct
Validation 1 Five study groups 1980–96 172 Good/int/poor 45 OK AUC=0.82 52/172 (30%) cons nec
from Europe 38/52 (73%) correct
Validation 2
a Indiana University 1985–99 276 Good/int/poor 28 Recalibration necessary AUC=0.79 24/276 (9%) cons nec
17/24 (71%) correct
Validation 3 EORTC/MRC trial 1995–98 105 Good 26 OK for predictions >5% AUC=0.76 4/105 (4%) cons
(present study) 3/4 (75%) correct
Calibration=agreement between predicted probabilities and observed frequencies, Discrimination=ability to distinguish a benign mass from tumour, AUC=area under the curve,
cons nec=masses considered as benign (predicted probability >70%), correct=masses correctly considered as benign (predicted probability >70% and histology benign).
aModified prediction rule.
Validity of predictions for residual mass histology
Y Vergouwe et al
846
British Journal of Cancer (2003) 88(6), 843–847 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yACKNOWLEDGEMENTS
Yvonne Vergouwe was supported by the Netherlands Organisation
for Scientific Research. Ewout W Steyerberg was supported by a
fellowship from the Royal Netherlands Academy of Arts and
Sciences.
REFERENCES
de Wit R, Roberts JT, Wilkinson P, de Mulder PHM, Mead GM, Fossa ˚ SD,
Cook P, de Prijck L, Stenning S, Collette L (2001) Final analysis
demonstrating the equivalence of 3 BEP vs. 4 cycles and the 5 day
schedule vs. 3 days per cycle in good prognosis germ cell cancer. An
EORTC/MRC phase III study. J Clin Oncol 19: 1629–1640
Donohue JP, Rowland RG, Kopecky K, Steidle CP, Geier G, Ney KG,
Einhorn L, Williams S, Loehrer P (1987) Correlation of computerized
tomographic changes and histological findings in 80 patients having
radical retroperitoneal lymph node dissection after chemotherapy for
testis cancer. J Urol 137: 1176–1179
Fossa ˚ SD, Qvist H, Stenwig AE, Lien HH, Ous S, Giercksky KE (1992) Is
postchemotherapy retroperitoneal surgery necessary in patients with
nonseminomatous testicular cancer and minimal residual tumor
masses?. J Clin Oncol 10: 569–573
Gelderman WA, Koops HS, Sleijfer DT, Oosterhuis JW, Oldhoff J (1986)
Treatment of retroperitoneal residual tumor after PVB chemotherapy of
nonseminomatous testicular tumors. Cancer 58: 1418–1421
Gels ME, Nijboer AP, Hoekstra HJ, Sleijfer DT, Molenaar WM, Plukker JT,
Droste JH, Schraffordt Koops H (1997) Complications of the post-
chemotherapy resection of retroperitoneal residual tumour mass in patients
with non-seminomatous testicular germ cell tumours. Br J Urol 79: 263–268
Harrell Jr FE (1997) Design: S-plus functions for biostatistical/epidemio-
logical modelling, testing, estimation, validation, graphics, prediction,
and typesetting by storing enhanced model design attributes in the fit.
Programs available at internet; http://lib.stat.cmu.edu/DOS/S/Harrell/
Harrell Jr FE, Califf RM, Pryor DB, Lee KL, Rosati RA (1982) Evaluating the
yield of medical tests. JAMA 247: 2543–2546
He X, Shen L (1997) Linear regression after spline transformation.
Biometrika 84: 474–481
Hosmer DW, Lemeshow S (1989) Applied Logistic Regression. New York:
John Wiley & Sons, Inc.
IGCCG (1997) International germ cell consensus classification: a prognostic
factor-based staging system for metastatic germ cell cancers. J Clin Oncol
15: 594–603
Jansen RL, Sylvester R, Sleyfer DT, ten Bokkel Huinink WW, Kaye SB, Jones
WG, Keizer HJ, van Oosterom AT, Meyer S, Vendrik CP (1991) Long-
term follow-up of non-seminomatous testicular cancer patients with
mature teratoma or carcinoma at postchemotherapy surgery. EORTC
Genitourinary tract Cancer Cooperative Group (EORTC GU Group). Eur
J Cancer 27: 695–698
Justice AC, Covinsky KE, Berlin JA (1999) Assessing the generalizability of
prognostic information. Ann Intern Med 130: 515–524
Mead GM, Stenning SP, Parkinson MC, Horwich A, Fossa ˚ SD, Wilkinson
PM, Kaye SB, Newlands ES, Cook PA (1992) The second medical research
council study of prognostic factors in nonseminomatous germ cell
tumors. J Clin Oncol 10: 85–94
Peckham M (1988) Testicular cancer. Rev Oncol 1: 439–453
Steyerberg EW, Gerl A, Fossa ˚ SD, Sleijfer DT, de Wit R, Kirkels WJ,
Schmeller N, Clemm C, Habbema JDF, Keizer HJ (1998) Validity of
predictions of residual retroperitoneal mass histology in nonseminoma-
tous testicular cancer. J Clin Oncol 16: 269–274
Steyerberg EW, Keizer HJ, Fossa ˚ SD, Sleijfer DT, Toner GC, Schraffordt
Koops H, Mulders PFA, Messemer JE, Ney K, Donohue JP, Bajorin DF,
Stoter G, Bosl GJ, Habbema JDF (1995) Prediction of residual
retroperitoneal mass histology following chemotherapy for metastatic
nonseminomatous germ cell tumor: multivariate analysis of individual
patient data from six study groups. J Clin Oncol 13: 1177–1187
Steyerberg EW, Marshall PB, Keizer JH, Habbema JDF (1999a) Resection of
small, residual retroperitoneal masses after chemotherapy for nonsemi-
nomatous testicular cancer: a decision analysis. Cancer 85: 1331–1341
Steyerberg EW, Keizer HJ, Habbema JDF (1999b) Prediction models for the
histology of residual masses after chemotherapy for metastatic testicular
cancer. Int J Cancer 83: 856–859
Vergouwe Y, Steyerberg EW, Foster RS, Habbema JDF, Donohue JP
(2001) Validation of a prediction model and its predictors for the
histology of residual masses in nonseminomatous testicular cancer. J
Urol 165: 84–88
Validity of predictions for residual mass histology
Y Vergouwe et al
847
British Journal of Cancer (2003) 88(6), 843–847 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y